Answer
Tibsovo (ivosidenib) alone is indicated for adults with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who have received at least one prior line of systemic therapy.
Sources for this answer
- TibsovoServier Laboratories Limited · emc · SmPC §4.1 Therapeutic Indications · Version 5Document updated
Sources checked